Barrington analyst Michael Petusky raised the firm’s price target on Surmodics to $71 from $69 and keeps an Outperform rating on the shares. The company delivered a fiscal Q4 beat and its 2024 guidance seems conservative, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SRDX:
